Real-world management of intraductal papillary mucinous neoplasms–findings from a nationwide survey
(2026) In Scandinavian Journal of Gastroenterology- Abstract
Background/objectives: A nationwide survey, covering all surgical departments, was conducted in a country with easily accessible tax-funded healthcare. The survey aimed to provide insight into ‘real-world’ intraductal papillary mucinous neoplasia (IPMN) surveillance, including the proportion of patients monitored, adherence to guidelines and details of follow-up. Methods: At all hospitals caring for IPMN patients in Sweden (n = 46), an upper-gastrointestinal surgeon received a survey by mail with clinically oriented questions, including a mix of Likert scale, multiple-choice and open-ended questions. Up to three reminders were sent. Results: Forty-five hospitals responded. In median 116 (10–1500) patients with IPMN were followed at each... (More)
Background/objectives: A nationwide survey, covering all surgical departments, was conducted in a country with easily accessible tax-funded healthcare. The survey aimed to provide insight into ‘real-world’ intraductal papillary mucinous neoplasia (IPMN) surveillance, including the proportion of patients monitored, adherence to guidelines and details of follow-up. Methods: At all hospitals caring for IPMN patients in Sweden (n = 46), an upper-gastrointestinal surgeon received a survey by mail with clinically oriented questions, including a mix of Likert scale, multiple-choice and open-ended questions. Up to three reminders were sent. Results: Forty-five hospitals responded. In median 116 (10–1500) patients with IPMN were followed at each hospital. At the hospital with the largest volume 14 physicians were involved in IPMN surveillance. In 9/45 hospitals, other professionals, such as registered nurses and secretaries, were actively involved in surveillance. All hospitals were aware of the national care program for IPMN, and all but three adhered to it. Nevertheless, uncertainty persisted about whether resources are being used wisely in branch duct (BD)-IPMN surveillance (yes/no/unsure; university hospital 2/4/0, county hospital 0/20/3 and district hospital 3/7/1). Comorbidity, older age, patient’s own decision, and a combination of age and stable radiological findings were reasons for ending surveillance. Twenty-eight of 45 responders believed that surveillance will be changed in 5 years and almost all, 42/45 in 10 years. Conclusions: Adherence to the national care program for IPMN was very good, although a majority questioned the current follow-up of BD-IPMN from a resource perspective. There is a strong belief that new knowledge will change the guidelines in the near future.
(Less)
- author
- Andersson, Bodil
LU
; Ghorbani, Poya
; Öman, Mikael
; Björnsson, Bergthor
; Wennerblom Hansson, Johanna
; Szepesvari, Robert
; Al-Jubouri, Muhammed
; Nilsson, Johan
LU
and Williamsson, Caroline
LU
- organization
-
- LUCC: Lund University Cancer Centre
- eSSENCE: The e-Science Collaboration
- Artificial Intelligence in CardioThoracic Sciences (AICTS) (research group)
- Hepato-Pancreato-Biliary Surgery (research group)
- Surgery (Lund)
- Artificial Intelligence and Bioinformatics in Cardiothoracic Sciences (AIBCTS) (research group)
- Heparin bindning protein in cardiothoracic surgery (research group)
- Heart and Lung transplantation (research group)
- Thoracic Surgery
- publishing date
- 2026
- type
- Contribution to journal
- publication status
- in press
- subject
- keywords
- cancer development, follow-up, guidelines, IPMN, premalignant, surveillance, survey
- in
- Scandinavian Journal of Gastroenterology
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:105033604098
- pmid:41866836
- ISSN
- 0036-5521
- DOI
- 10.1080/00365521.2026.2642822
- language
- English
- LU publication?
- yes
- id
- 913de3d5-112f-4688-b639-2f5fe3f3176a
- date added to LUP
- 2026-05-21 14:21:06
- date last changed
- 2026-06-04 15:18:34
@article{913de3d5-112f-4688-b639-2f5fe3f3176a,
abstract = {{<p>Background/objectives: A nationwide survey, covering all surgical departments, was conducted in a country with easily accessible tax-funded healthcare. The survey aimed to provide insight into ‘real-world’ intraductal papillary mucinous neoplasia (IPMN) surveillance, including the proportion of patients monitored, adherence to guidelines and details of follow-up. Methods: At all hospitals caring for IPMN patients in Sweden (n = 46), an upper-gastrointestinal surgeon received a survey by mail with clinically oriented questions, including a mix of Likert scale, multiple-choice and open-ended questions. Up to three reminders were sent. Results: Forty-five hospitals responded. In median 116 (10–1500) patients with IPMN were followed at each hospital. At the hospital with the largest volume 14 physicians were involved in IPMN surveillance. In 9/45 hospitals, other professionals, such as registered nurses and secretaries, were actively involved in surveillance. All hospitals were aware of the national care program for IPMN, and all but three adhered to it. Nevertheless, uncertainty persisted about whether resources are being used wisely in branch duct (BD)-IPMN surveillance (yes/no/unsure; university hospital 2/4/0, county hospital 0/20/3 and district hospital 3/7/1). Comorbidity, older age, patient’s own decision, and a combination of age and stable radiological findings were reasons for ending surveillance. Twenty-eight of 45 responders believed that surveillance will be changed in 5 years and almost all, 42/45 in 10 years. Conclusions: Adherence to the national care program for IPMN was very good, although a majority questioned the current follow-up of BD-IPMN from a resource perspective. There is a strong belief that new knowledge will change the guidelines in the near future.</p>}},
author = {{Andersson, Bodil and Ghorbani, Poya and Öman, Mikael and Björnsson, Bergthor and Wennerblom Hansson, Johanna and Szepesvari, Robert and Al-Jubouri, Muhammed and Nilsson, Johan and Williamsson, Caroline}},
issn = {{0036-5521}},
keywords = {{cancer development; follow-up; guidelines; IPMN; premalignant; surveillance; survey}},
language = {{eng}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Gastroenterology}},
title = {{Real-world management of intraductal papillary mucinous neoplasms–findings from a nationwide survey}},
url = {{http://dx.doi.org/10.1080/00365521.2026.2642822}},
doi = {{10.1080/00365521.2026.2642822}},
year = {{2026}},
}